A 41-year-old man was evaluated for swelling in the ankles and syncope. CT of the chest showed bilateral mediastinal and ...

Few procedures have gone through a decade of practice-changing clinical trials as impressive as thrombectomy for stroke. Beginning in 2015 with multiple trials showing a benefit with thrombectomy ...

A total of 867 patients underwent randomization: 291 were assigned to receive acalabrutinib–venetoclax, 286 acalabrutinib–venetoclax–obinutuzumab, and 290 chemoimmunotherapy (of whom 143 ...

Whether the large effect size of endovascular thrombectomy (EVT) for stroke due to large-vessel occlusion applies to stroke due to medium-vessel occlusion is unclear. In a multicenter, prospective ...

Endovascular treatment (EVT) of stroke with large-vessel occlusion is known to be safe and effective. The effect of EVT for occlusion of medium or distal vessels is unclear. We randomly assigned ...

Familial HLH is a success story in modern medicine. Initially a disease that was largely unknown and fatal, it is now understood on a molecular level and is curable. Moreover, HLH is an archetype ...

LYSOZYME, a bacteriolytic enzyme discovered in 1922 by Sir Alexander Fleming, 2 is found in a number of biologic fluids. The enzyme is a basic protein of low molecular weight that lyses ...

Malignant T-cell transformation after chimeric antigen receptor (CAR) T-cell therapy has been described, but the contribution of CAR integration to oncogenesis is not clear. Here we report a case ...

Obinutuzumab, a humanized type II anti-CD20 monoclonal antibody, provided significantly better renal responses than placebo in a phase 2 trial involving patients with lupus nephritis receiving ...

Supported by the Advanced Research Projects Agency for Health (agreement number, 140D042490001); a grant (R01HL141408) from the National Heart, Lung, and Blood Institute; a grant (R01FD007632 ...

CME activities, cases, challenges, videos, and more teaching and learning tools from the New England Journal of Medicine.

Welcome and thank you for considering the New England Journal of Medicine (NEJM) as a venue for your work. As the oldest continuously-published medical journal, our mission since 1812 has been to ...